Kate Baker, DVM, MS, DACVP (Clinical Pathology) explained that although cytology can be challenging, it might be easier than ...

which was highlighted in the capital structure slide. The company now expects its underlying EBITDA to be in the lower half of the previously announced range of €1.0 billion to €1.1 billion.

Cost Structure & Synergies A key focus for California Resources has been enhancing its cost structure following the Aera merger. The company reported a 7% quarter-over-quarter decrease in non-energy ...

CRC is targeting a ~15% improvement in its 2025 controllable cost structure compared to the pro forma 2023 baseline. ... The following slide illustrates CRC’s leadership in California’s ...

Finding a simple and effective strategy to eliminate tumor metastatic lymph nodes is highly desired in clinical tumor treatment. Herein, we reported a Chinese traditional ink (Hu-ink)-based treatment ...